Loperamide

Major

Loperamide Quizartinib Vanflyta An increased risk of QT interval prolongation Details Loperamide Ranitidine Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Ranolazine Aspruzyo An increased risk of QT interval prolongation, an increased risk of other ventricular arrhythmias, cardiac arrest, an increased lo... Details Loperamide Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Loperamide Resmetirom Rezdiffra An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Resveratrol Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Ribociclib Kisqali Increased loperamide exposure, an increased risk of loperamide-related adverse effects and an increased risk of QT interval prolon... Details Loperamide Rifampin Rifadin Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Rilpivirine Edurant An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Rimegepant Nurtec Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Risperidone Perseris An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Ritlecitinib Litfulo Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Ritonavir Norvir Increased loperamide exposure, an increased risk of loperamide-related adverse reaction, an increased risk of QT interval prolonga... Details Loperamide Rolapitant Varubi An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Rucaparib Rubraca An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Sarecycline Seysara Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Schizandra An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Segesterone Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Selpercatinib Retevmo Increased loperamide exposure, an increased risk of loperamide-related adverse effects and an increased risk of QT interval prolon... Details Loperamide Sertindole An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Sevoflurane Petrem An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Simeprevir Olysio® An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Siponimod Mayzent An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Sodium Phosphate OsmoPrep An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Sodium Phosphate, Dibasic An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Sodium Phosphate, Monobasic An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Solifenacin Vesicare An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Sorafenib Nexavar An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Sotagliflozin Inpefa Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Sotalol Betapace An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Sotorasib Lumakras Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Spironolactone Aldactone Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Loperamide Stiripentol Diacomit Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Sulpiride An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Sultopride An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Sunitinib Sutent An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Suvorexant Belsomra An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Loperamide Tacrolimus Astagraf An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Taletrectinib Ibtrozi An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details Loperamide Tamoxifen Nolvadex® An increased risk of QT interval prolongation, which may increase risk of cardiotoxicity (torsade de pointes, cardiac arrest) Details